Lipid-Lowering Therapy and Diabetes: Where Does Fish Oil Fit In?
Moderate intake of long chain omega-3 polyunsaturated fatty acids as a lipid-lowering strategy appears to have no effects on glucose regulation or insulin resistance.
Moderate intake of long chain omega-3 polyunsaturated fatty acids as a lipid-lowering strategy appears to have no effects on glucose regulation or insulin resistance.
For patients with elevated cholesterol, life-style changes are primary, but goals are often unattainable through these interventions alone.
Lipid-lowering drugs are used to augment lifestyle changes, and
The June 2014 issue of Cardiovascular Drugs and Therapy contains a comprehensive
Among the agents discussed in the article is supplemental fish oil, which contains long chain omega-3 polyunsaturated fatty acids (n-3 PUFA) predominantly in the form of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
Dyslipidemic individuals treated with fish oil can reduce triglyceride levels by 20% to 50%, and may also increase HDL and LDL cholesterol levels slightly. A key reason for using fish oils to treat dyslipidemia is their possible anti-arrhythmic, antithrombotic, and anti-inflammatory effects on the cardiovascular system.
The authors review population-based studies that suggest fish and seafood intake may reduce the risk of impaired glucose tolerance and incidence of type 2 diabetes, although results are mixed. The authors indicate that study design variations, particularly in the amount, duration, and fatty acid composition of fish oils, account for the different findings. Older studies using very high doses of fish oils tended to report correlations between highest amount of fish consumed and risk for type 2 diabetes.
Several later meta-analyses found no significant association between fish oil supplementation and fasting glucose or HgbA1c in diabetic patients.
Fish oils may reverse, reduce, and prevent diet-induced insulin resistance. The authors indicate that substituting unsaturated fat for saturated fat may improve insulin sensitivity. They cover a variety of mechanisms by which insulin resistance may be reduced, including their known anti-inflammatory effect.
The authors conclude that moderate n-3 PUFA intake as a lipid-lowering strategy has been studied and appears to have no effects on glucose regulation or insulin resistance. The association with development of diabetes is weak at best.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025